ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2017
The sensitivity of the QuantiFERON
Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Pooled it
- Interpretation of serial interferon-gamma test results to measure new tuberculosis infection among household contacts in Zambia and South Africa.BMC infectious diseases · 2020Trial
- Risk Factors Associated With Tuberculosis Infection Among Household Contacts of Patients With Microbiologically Confirmed Pulmonary Tuberculosis in 3 High Tuberculosis Burden Countries.The Journal of infectious diseases · 2025Article
- Preliminary performance of the VIDAS TB-IGRA as an aid in the diagnosis of individuals infected withJournal of clinical microbiology · 2025Article
- High prevalence of co-infections with latent tuberculosis, syphilis and hepatitis B and C among people with HIV in Ghana: a call for integrating screening into routine care.AIDS research and therapy · 2025Article
- Evaluation of QuantiFERON TB gold plus among TB household contacts in high incidence settings.BMC infectious diseases · 2025Article
- Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Article
- Performance comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in detectingPeerJ · 2025Article
- Efficacy and Risk Factors of Interferon-Gamma Release Assays among HIV-Positive Individuals.International journal of environmental research and public health · 2023Article
- Mycobacterium tuberculosis-specific cytokine responses according to HIV status among household contacts of people with TB.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Prevalence and risk factors of M tuberculosis infection in young people across 14 communities in Zambia and South Africa.PLOS global public health · 2023Article
- The impact of a combined TB/HIV intervention on the incidence of TB infection among adolescents and young adults in the HPTN 071 (PopART) trial communities in Zambia and South Africa.PLOS global public health · 2023Article
- Evaluation of the performance of QuantiFERON®-TB Gold plus test in active tuberculosis patients.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Phenotype Definition for "Resisters" toFrontiers in immunology · 2021Review
- Role of interferon gamma release assay in the diagnosis and management ofBMJ open ophthalmology · 2021Review
- Comparing QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube for diagnosis of latent tuberculosis infection among highly TB exposed gold miners in South Africa.Gates open research · 2021Article
- Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?Journal of clinical microbiology · 2020Review
- Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.The Journal of infection · 2020Article
- Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
SETTING AND
objectiveTo investigate the sensitivity of the new interferon-gamma release assay (IGRA), QuantiFERON®-TB Gold Plus (QFT-Plus), for active TB (used as a surrogate for latent tuberculous infection) in a Zambian TB clinic.
designConsecutive smear or Xpert® MTB/RIF-positive adult (age 18 years) pulmonary TB patients were recruited between June 2015 and March 2016. Venous blood was tested using QFT-Plus. The sensitivity was defined as the number positive divided by the total number tested. Using logistic regression, factors associated with positive QFT-Plus results were explored.
resultsOf 108 patients (median age 32 years, interquartile range 27-38; 73% male; 63% human immunodeficiency virus [HIV] positive), 90 were QFT-Plus-positive, 11 were negative and seven had indeterminate results; sensitivity was 83% (95%CI 75-90). There was no difference in sensitivity by HIV status (HIV-positive 85%, 95%CI 75-93; n = 68 vs. HIV-negative 80%, 95%CI 64-91; n = 40; P = 0.59). In models adjusted for age alone, CD4 cell count <100 cells/μl (OR 0.15, 95%CI 0.02-0.96; P = 0.05) and body mass index <18.5 kg/m2 (OR 0.27, 95%CI 0.08-0.91; P = 0.02) were associated with decreased odds of positive QFT-Plus results.
conclusionOverall, the sensitivity of QFT-Plus is similar to that of the tuberculin skin test and other IGRAs. While overall sensitivity is not affected by HIV status, QFT-Plus sensitivity was lower among people living with HIV/acquired immune-deficiency syndrome with severe immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.